, Global epidemiology of hepatitis C virus infection, The Lancet Infectious Diseases, vol.5, issue.9, pp.558-67, 2005.
DOI : 10.1016/S1473-3099(05)70216-4
, Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C, Gastroenterology, vol.122, issue.5, pp.1303-1316, 2002.
DOI : 10.1053/gast.2002.33023
, Antiviral Therapy for Cirrhotic Hepatitis C: Association with Reduced Hepatocellular Carcinoma Development and Improved Survival, Annals of Internal Medicine, vol.142, issue.2, pp.105-119, 2005.
DOI : 10.7326/0003-4819-142-2-200501180-00009
, Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.347, issue.13, pp.975-82, 2002.
DOI : 10.1056/NEJMoa020047
, Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection, New England Journal of Medicine, vol.361, issue.6, pp.580-93, 2009.
DOI : 10.1056/NEJMoa0808010
, Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.364, issue.25, pp.2405-2421, 2011.
DOI : 10.1056/NEJMoa1012912
URL : http://hdl.handle.net/2318/97842
, Telaprevir for Retreatment of HCV Infection, New England Journal of Medicine, vol.364, issue.25, pp.2417-2445, 2011.
DOI : 10.1056/NEJMoa1013086
, Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1207-1224, 2011.
DOI : 10.1056/NEJMoa1009482
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153125
, Boceprevir for Untreated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1195-1206, 2011.
DOI : 10.1056/NEJMoa1010494
URL : https://hal.archives-ouvertes.fr/hal-00867494
, 477 ANEMIA HAD NO EFFECT ON EFFICACY OUTCOMES IN TREATMENT-NAIVE PATIENTS WHO RECEIVED TELAPREVIR-BASED REGIMEN IN THE ADVANCE AND ILLUMINATE PHASE 3 STUDIES, Journal of Hepatology, vol.54, p.195, 2011.
DOI : 10.1016/S0168-8278(11)60479-0
, 476 ANEMIA DURING TREATMENT WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN WITH OR WITHOUT BOCEPREVIR IS ASSOCIATED WITH HIGHER SVR RATES: ANALYSIS OF PREVIOUSLY UNTREATED AND PREVIOUS-TREATMENT-FAILURE PATIENTS, Journal of Hepatology, vol.54, p.194, 2011.
DOI : 10.1016/S0168-8278(11)60478-9
, Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment, Clinical Gastroenterology and Hepatology, vol.5, issue.1, pp.124-133, 2007.
DOI : 10.1016/j.cgh.2006.10.008
, Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study1 1The other PROACTIVE Study Group investigators included the following: Vijayan Balan, M.D., Mayo Clinic Scottsdale, Scottsdale, Arizona; Norbert Br??u, M.D., Bronx VA Medical Center, Bronx, New York; Robert Brown, M.D., M.P.H., NY Presbyterian Medical Center, New York, New York; William Carey, M.D., Cleveland Clinic Foundation, Cleveland, Ohio; Andrea Duchini, M.D., Baylor College of Medicine, Houston, Texas; Greg Everson, M.D., University of Colorado Health Sciences Center, Denver, Colorado; Michael Fried, M.D., University of North Carolina, Chapel Hill, North Carolina; Robert Gish, M.D., California Pacific Medical Center, San Francisco, California; Ira Jacobson, M.D., Weill Medical College of Cornell University, New York, New York; John W. King, LSU Health Sciences Center, Shreveport, LA; Raymond Koff, M.D., University of Massachusetts Memorial Health Care, Worcester, Massachusetts; William Lee, M.D., University of Texas Southwestern Medical Center, Dallas, Texas; Mark A. Levstik, M.D., The University of Tennessee, Memphis, Tennessee; John G. McHutchison, M.D., Scripps Clinic, La Jolla, California; Marion Peters, M.D., University of California San Francisco, San Francisco, California; Kenneth Sherman, M.D., Ph.D., University of Cincinnati College of Medicine, Cincinnati, Ohio; Coleman Smith, M.D., Minnesota Clinical Research Center, St. Paul, MN; Ronald Wasserman, M.D., Hepatitis Resource Center, Walnut Creek, California., Gastroenterology, vol.126, issue.5, pp.1302-1313, 2004.
DOI : 10.1053/j.gastro.2004.01.027
, Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate, Gastroenterology, vol.139, issue.5, pp.1602-1613, 2010.
DOI : 10.1053/j.gastro.2010.07.059
, Safety of telaprevir or boceprevir in combination with peginterferonalfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC) in real-life setting
, Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases, British Journal of Dermatology, vol.14, issue.5, pp.1088-90, 2005.
DOI : 10.1046/j.1365-2133.2002.04897.x
, Dermatological side effects, Hot Topics in Viral Hepatitis, vol.9, pp.29-35, 2008.
, Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals, Journal of Hepatology, vol.56, issue.2, 2011.
DOI : 10.1016/j.jhep.2011.08.006
, Drug Rash with Eosinophilia and Systemic Symptoms due to Telaprevir, Dermatology, vol.221, issue.4, pp.303-308, 2010.
DOI : 10.1159/000318904
, Initial management of a major burn: II--assessment and resuscitation, BMJ, vol.329, issue.7457, pp.101-104, 2044.
DOI : 10.1136/bmj.329.7457.101
, Antiretroviral drug interactions:often unrecognized, frequently unavoidable, sometimes unmanageable, J Antimicrobchemother, vol.64, pp.5-8, 2009.
, Low-dose RTV and the pharmacokinetics of the investigational HCV protease inhibitor TVR in Healthy volunteers, 18 th Conference on Retroviruses and Opportunistic Infections, 2011.
, Clinical pharmacology of BOC:metabolism, excretion, and drug-drug interactions, 18 th Conference on Retroviruses and Opportunistic Infections, 2011.
, New direct-acting antivirals' combination for the treatment of chronic hepatitis C, Liver International, vol.376, issue.1, pp.68-77, 2011.
DOI : 10.1111/j.1478-3231.2010.02411.x